Salivary Glands and Periodontal Changes in a Population of Sjögren's and Sicca Syndrome Treated by Pilocarpine: A Pilot Study.
Pilocarpine
Salivary glands
Sjögren’s syndrome
Ultrasonography
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
13
10
2020
accepted:
26
11
2020
pubmed:
19
12
2020
medline:
19
12
2020
entrez:
18
12
2020
Statut:
ppublish
Résumé
Oral administration of pilocarpine enhances salivary flow in sicca patients but its effect upstream on ultrasound (US) of salivary glands (SG) and downstream on periodontium remain unknown. Sicca patients were prospectively included. Echostructural and vascularization of SG were assessed using B mode and pulsed Doppler (USPD). Vascularization of SG was measured using resistive index (RI) before and after stimulation by lemon juice. Echostructure (measure of glandular length in cm Nineteen patients were included but only 11 received pilocarpine treatment for 3 months, as six stopped pilocarpine due to side effects and two were excluded for other causes. Among the 11 patients who completed the 3-month follow-up, five had primary Sjögren's syndrome according to the American-European's classification criteria. As expected, statistical differences were found concerning SSF (p = 0.018) and USSF (p = 0.027) between M0 and M3 while no statistical change in both SG echostructure and vascularization or periodontal evaluation was shown. Pilocarpine improved SSF and USSF measurements in sicca syndrome but no ultrasonography of major salivary glands (SGUS) structural and vascular changes were detected as well as periodontal evaluation.
Identifiants
pubmed: 33336287
doi: 10.1007/s40744-020-00263-y
pii: 10.1007/s40744-020-00263-y
pmc: PMC7990995
doi:
Types de publication
Journal Article
Langues
eng
Pagination
219-231Références
Delli K, Spijkervet FK, Kroese FG, Bootsma H, Vissink A. Xerostomia. Monogr Oral Sci. 2014;24:109–25.
doi: 10.1159/000358792
Milin M, Cornec D, Chastaing M, et al. Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjögren’s syndrome. Joint Bone Spine. 2016;83(6):681–5.
doi: 10.1016/j.jbspin.2015.10.005
Takagi Y, Sumi M, Nakamura H, Sato S, Kawakami A, Nakamura T. Salivary gland ultrasonography as a primary imaging tool for predicting efficacy of xerostomia treatment in patients with Sjögren’s syndrome. Rheumatology (Oxford). 2016;55(2):237–45.
doi: 10.1093/rheumatology/kev278
Kim JW, Lee H, Park SH, Kim SK, Choe JY, Kim JK. Salivary gland ultrasonography findings are associated with clinical, histological, and serologic features of Sjögren’s syndrome. Scand J Rheumatol. 2018;7:1–8.
De Vita S, Lorenzon G, Rossi G, Sabella M, Fossaluzza V. Salivary gland echography in primary and secondary Sjögren’s syndrome. Clin Exp Rheumatol. 1992;10(4):351–6.
pubmed: 1395220
Chikui T, Yonetsu K, Izumi M, Eguchi K, Nakamura T. Abnormal blood flow to the submandibular glands of patients with Sjögren’s syndrome: doppler waveform analysis. J Rheumatol. 2000;27(5):1222–8.
pubmed: 10813291
Martinoli C, Derchi LE, Solbiati L, Rizzatto G, Silvestri E, Giannoni M. Color Doppler sonography of salivary glands. AJR Am J Roentgenol. 1994;163(4):933–41.
doi: 10.2214/ajr.163.4.8092039
Jousse-Joulin S, Devauchelle-Pensec V, Morvan J, et al. Ultrasound assessment of salivary glands in patients with primary Sjögren’s syndrome treated with rituximab: quantitative and Doppler waveform analysis. Biologics. 2007;1(3):311–9.
pubmed: 19707340
pmcid: 2721315
Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome. Nat Rev Rheumatol. 2016;12(8):456–71.
doi: 10.1038/nrrheum.2016.100
Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92–01 study group. Arch Intern Med. 1999;159(2):174–81.
doi: 10.1001/archinte.159.2.174
Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren’s syndrome in Taiwan–a double-blind placebo-controlled trial. J Formos Med Assoc. 2006;105(10):796–803.
doi: 10.1016/S0929-6646(09)60266-7
Nakamura N, Sasano N, Yamashita H, et al. Oral pilocarpine (5mg t.i.d) used for xerostomia causes adverse effects in Japanese. Auris Nasus Larynx. 2009;36(3):310–3.
doi: 10.1016/j.anl.2008.04.008
Berk L. Systemic pilocarpine for treatment of xerostomia. Expert Opin Drug Metab Toxicol. 2008;4(10):1333–40.
doi: 10.1517/17425255.4.10.1333
Tanigawa T, Yamashita J, Sato T, et al. Efficacy and safety of pilocarpine mouthwash in elderly patients with xerostomia. Spec Care Dentist. 2015;35(4):164–9.
doi: 10.1111/scd.12105
Cifuentes M, Del Barrio-Díaz P, et Vera-Kellet C. Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia of Sjögren’s syndrome: a double-blind control trial. Br J Dermatol. 2018.
Carotti M, Salaffi F, Manganelli P, Argalia G. Ultrasonography and colour Doppler sonography of salivary glands in primary Sjögren’s syndrome. Clin Rheumatol. 2001;20(3):213–9.
doi: 10.1007/s100670170068
Cornec D, Jousse-Joulin S, Pers JO, et al. Contribution of salivary gland ultrasonography to the diagnosis of Sjögren’s syndrome: toward new diagnostic criteria? Arthritis Rheum. 2013;65(1):216–25.
doi: 10.1002/art.37698
Jousse-Joulin S, D’Agostino MA, Nicolas C, et al. Video clip assessment of a salivary gland ultrasound scoring system in Sjögren’s syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise. Ann Rheum Dis. 2019;78(7):967–73.
doi: 10.1136/annrheumdis-2019-215024
Ramfjord SP. The periodontal disease index (PDI). J Periodontol. 1967;38(Suppl):602–10. https://doi.org/10.1902/jop.1967.38.6.602 .
doi: 10.1902/jop.1967.38.6.602
Pers JO, Saraux A, Pierre R, Youinou P. Anti-TNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. J Periodontol. 2008;79(9):1645–51.
doi: 10.1902/jop.2008.070616
Silness J, Loe H. Periodontal disease in pregnancy. Ii. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand. 1964;22:121–35.
doi: 10.3109/00016356408993968
Lobene RR, Weatherford T, Ross NM, Lamm RA, Menaker L. A modified gingival index for use in clinical trials. Clin Prev Dent. 1986;8(1):3–6.
pubmed: 3485495
Le Gall M, Cornec D, Pers JO, et al. A prospective evaluation of dental and periodontal status in patients with suspected Sjögren’s syndrome. Joint Bone Spine. 2016;83(2):235–6.
doi: 10.1016/j.jbspin.2015.02.015
Le Goff M, Cornec D, Jousse-Joulin S, et al. Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren’s syndrome. Arthritis Res Ther. 2017;19(1):269.
doi: 10.1186/s13075-017-1475-x
Fisher BA, Everett CC, Rout J, et al. Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Ann Rheum Dis. 2018;77(3):412–6.
doi: 10.1136/annrheumdis-2017-212268
Luciano N, Baldini C, Tarantini G, et al. Ultrasonography of major salivary glands: a highly specific tool for distinguishing primary Sjögren’s syndrome from undifferentiated connective tissue diseases. Rheumatology (Oxford). 2015;54(12):2198–204.
Carotti M, Ciapetti A, Jousse-Joulin S, Salaffi F. Ultrasonography of the salivary glands: the role of grey-scale and colour/power Doppler. Clin Exp Rheumatol. 2014;32(1 Suppl 80):S61-70.
pubmed: 24528823
Hendrickson RG, Morocco AP, Greenberg MI. Pilocarpine toxicity and the treatment of xerostomia. J Emerg Med. 2004;26(4):429–32.
doi: 10.1016/j.jemermed.2003.09.013
Zimmerman TJ, Wheeler TM. Miotics: side effects and ways to avoid them. Ophthalmology. 1982;89(1):76–80.
doi: 10.1016/S0161-6420(82)34866-6
Noaiseh G, Baker JF, Vivino FB. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2014;32(4):575–7.
pubmed: 25065774
Brimhall J, Jhaveri MA, Yepes JF. Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study. Spec Care Dentist. 2013;33(3):123–7.
doi: 10.1111/scd.12010
Bernardi R, Perin C, Becker FL, et al. Effect of pilocarpine mouthwash on salivary flow. Braz J Med Biol Res. 2002;35(1):105–10.
doi: 10.1590/S0100-879X2002000100015
Christensen LB, Petersen PE, Torn JJ, Schiodt M. Dental caries and dental health behavior of patients with primary Sjögren syndrome. Acta Odontol Scand. 2001;59(3):116–20.
doi: 10.1080/000163501750266684
Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A. Progression of salivary gland dysfunction in patients with Sjögren’s syndrome. Ann Rheum Dis. 2007;66(1):107–12.
doi: 10.1136/ard.2006.052647